Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Ligand Reports Third Quarter 2018 Financial Results
Ligand to Participate in Stephens NY Investment Conference
Ligand to Report Third Quarter 2018 Results on November 8th
Ligand Announces the Close of its Acquisition of Vernalis
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Ligand Reports Second Quarter 2018 Financial Results
Ligand to Report Second Quarter 2018 Results on August 6th
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Ligand Prices Offering of $650 Million of Convertible Senior Notes
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
Ligand to Participate in Upcoming Investor Conferences
